Canaccord Genuity
Canaccord Genuity is the global capital markets division of Canaccord Financial Inc. (CF : TSX | CF. : AIM), offering institutional and corporate clients idea-driven investment banking, research, sales and trading services.
The companies has operations in 24 cities worldwide and the ability to list companies on 10 stock exchanges.
View Older Stories View More Recent Stories
-
Aldeyra Therapeutics to Present at the Canaccord Genuity 35th Annual Growth Conference
-
MiX Telematics to Present at the Canaccord Genuity 35th Annual Growth Conference
-
Ultratech to Present at Canaccord Genuity Growth Conference on August 13
-
FARO to present at Canaccord Genuity 35th Annual Growth Conference
-
Alere to Participate in 35th Annual Canaccord Genuity Growth Conference
-
Alnylam to Webcast Presentation at Canaccord Genuity 35th Annual Growth Conference
-
Zynerba Pharmaceuticals (ZYNE) IPO Opens Up 29% Higher
-
Canaccord Genuity Raises Price Target on Charter Communications (CHTR) to $210 Following 2Q Results
-
pdvWireless to Present at the Canaccord Genuity 35th Annual Growth Conference on August 12th
-
Merit Medical to Present at Canaccord Genuity Growth Conference
-
Aquinox Pharmaceuticals to Present at the Canaccord Genuity 35th Annual Growth Conference
-
Mizuho Securities USA Announces Three New Hires in Their Equity Distribution Division
-
Inuvo to Present at the 35th Annual Canaccord Genuity Growth Conference
-
Digi International to Present at Upcoming Investor Conferences
-
Apricus Biosciences to Present at the Canaccord Genuity 35th Annual Growth Conference
-
Lipocine to Present at 35th Annual Canaccord Genuity Growth Conference
-
Lipocine to Present at 35th Annual Canaccord Genuity Growth Conference
-
CPI Aerostructures to Participate in Upcoming Investor Conferences
-
CryoLife to Present at Canaccord Genuity 35th Annual Growth Conference
-
Vonage Chief Executive Officer to Present at Upcoming Investor Conferences
-
Glu Mobile to Present at Upcoming Conferences
-
Kite Pharma to Present at the Canaccord Genuity 35th Annual Growth Conference
-
G1 Therapeutics to Present at August Investor Conferences
-
Sequential Brands Group to Present at the Canaccord Genuity 35th Annual Growth Conference
-
Abaxis, Inc. to Present at the Canaccord Genuity 35th Annual Growth Conference
-
G1 Therapeutics to Present at August Investor Conferences
-
Canaccord Genuity Downgrades Thoratec (THOR) to Hold
-
Canaccord Genuity Downgrades Alphatec Holdings (ATEC) to Hold
-
Agios to Present at Canaccord Genuity 35th Annual Growth Conference Wednesday, August 12, 2015
-
Acorda Therapeutics to Present at the Canaccord Genuity Growth Conference
-
Cerulean to Present at Two Upcoming Conferences
-
EnteroMedics to Present at the Canaccord Genuity 35th Annual Growth Conference
-
T2 Biosystems to Present at Canaccord Genuity Growth Conference
-
SAGE Therapeutics to Present at the Canaccord Genuity 35th Annual Growth Conference
-
SAGE Therapeutics to Present at the Canaccord Genuity 35th Annual Growth Conference
-
Accelerate Diagnostics to Present at the 35th Annual Canaccord Genuity Growth Conference on August 13, 2015
-
Retail Opportunity Investments Corp. Announces Pricing of Upsized Offering of Common Stock
-
Retail Opportunity Investments Corp. Announces Pricing of Upsized Offering of Common Stock
-
Zynerba Pharmaceuticals (ZYNE) Prices 3M Common Stock IPO at $14/Share
-
Zynerba Pharmaceuticals Announces Pricing of Its Initial Public Offering
-
Zynerba Pharmaceuticals Announces Pricing of Its Initial Public Offering
-
NOVADAQ to Present at the Canaccord Genuity 35th Annual Growth Conference
-
NOVADAQ to Present at the Canaccord Genuity 35th Annual Growth Conference
-
GoldMoney Inc. to Present at Canaccord Genuity Growth Conference
-
Versartis to Present at the Canaccord Genuity 35th Annual Growth Conference
-
RingCentral to Present at Upcoming Investor Conferences
-
Aspen Aerogels to Present at the Canaccord Genuity Growth Conference
-
Canaccord Genuity Group Inc. reports first quarter fiscal 2016 results
-
Hologic to Present at Upcoming Investor Conferences
-
Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares


